<PAGE>
EXHIBIT 1
[LOGO] NEWS RELEASE
PATHOGENESIS CORPORATION . 201 ELLIOTT AVENUE WEST, SEATTLE, WASHINGTON 98119
------------------------ --------------------------------------------------
(206) 467-8100
--------------
FOR IMMEDIATE RELEASE
Contact:
Alan Meyer, Chief Financial Officer
(847) 583-5421 or (206) 270-3328
PATHOGENESIS CORP. TO EXPLORE STRATEGIC OPTIONS
-----------------------------------------------
Continues on Track to Meet 2000 Expectations
SEATTLE, June 5, 2000 - PathoGenesis Corp. (Nasdaq: PGNS) today
announced that it has engaged Goldman Sachs & Co. and other advisors to explore
strategic options for enhancing shareholder value.
"PathoGenesis continues to be on track to meet Wall Street analysts'
current range of expectations for 2000," said Wilbur H. Gantz, chairman and
chief executive officer. "Although we are a small and relatively young biotech
company, we are well-capitalized. We have very strong research and development
capabilities, in addition to our manufacturing, sales and marketing strengths.
We are the world leader in the field of inhaled antibiotic therapy for
infectious diseases and have an exciting pipeline. At the same time, we
recognize the need to take PathoGenesis to the next level, to further broaden
our product line and markets, and to exploit our potential to the fullest."
Seattle-based PathoGenesis Corp. develops and commercializes drugs to treat
chronic infectious diseases - particularly serious lung infections - including
those common in cystic fibrosis, bronchiectasis and ventilator patients.
PathoGenesis' stock is traded on the Nasdaq National Market System under the
symbol PGNS. The company's Web site is located at www.pathogenesis.com.
Note: This news release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995. Because those
statements are based on factors that involve risks and uncertainties, the
company's actual future results may differ materially from the results expressed
or implied by the forward-looking statements. Factors that might cause such a
difference include, but are not limited to, uncertainties related to the fact
that PathoGenesis only began commercial operations in 1998, its dependence on
TOBI, the degree of penetration of its markets and frequency of TOBI's use by
patients, risks associated with marketing TOBI in international markets, third
party reimbursement and product pricing, seasonal impacts on hospitalizations or
exacerbations experienced by patients, variability in wholesaler ordering
patterns, uncertain outcome of drug development and clinical trials, uncertain
outcome of the U.S. and international drug approval process, competition and
alternative therapies, and other factors described in PathoGenesis' filings with
the Securities and Exchange Commission, including the company's 1999 annual
report on Form 10-K and Exhibit 99.1 to the Form 10-K.
# # # # #
